Peridot Acquisition Corp. Class A PDAC 深 沪
等待开盘 09-18 09:30:00 美东时间
11.23
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 11.23
- 总市值 4.21亿
- 52周最高 125.92
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 70.48
- 委 比 0.00%
- 总股本 3750.00万
- 历史最高 125.92
- 量 比 0
- 振 幅 0.00%
- 历史最低 70.48
- 每 手 1
- 风险率 0.15%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August...
09-17 00:29
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announc...
09-16 19:00
BioNTech杀疯了
（来源：药剂Talks） mRNA疫苗巨头BioNTech正在狂奔。 6月2日，百时美施贵宝（BMS）宣布就PD-L1/VEGF双抗BNT327（普米斯生物的...
09-12 09:15
Biggest stock movers Thursday: OPEN, RNA, and more
Stock futures ticked higher Thursday after the S&P 500 and Nasdaq closed at record highs, with investors eagerly awaiting key CPI data. Here are some of Thursday's biggest stock movers: Biggest stock ...
09-11 16:30
I-Mab Accelerates Givastomig Development With Global Phase 2 Trial In Metastatic Gastric Cancer; Expands Pipeline, And Appoints Wei Fu As Executive Chairman
Expands investment in givastomig in 1L metastatic gastric cancers, with plans to initiate a global randomized Phase 2 study in combination with immunochemotherapy, in Q1 2026, with additional Phase 1b cohorts to
09-08 20:39
【拔萃资本｜投资企业新闻】首届“斯蒂芬森全球奖”授予 RAS 癌症研究先驱 Frank McCormick 博士
（来源：拔萃资本） 斯蒂芬森全球奖（Stephenson Global Prize）近日公布首位获奖者，授予Frank McCormick 博士这一荣誉，以及...
09-06 16:10
二代IO争霸，暗藏哪些玄机？
（来源：药剂Talks） 下一代肿瘤“药王”，极有可能诞生于PD-(L)1 Plus领域。 以K药为代表的PD-1单抗，开启了一代IO（肿瘤免疫治疗）时代，但...
09-04 07:52
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 28, 2025 /PRNewswire/ -- Federal budget cuts have put pressure on cancer research efforts in th...
08-28 22:44
Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- USA News Group News Commentary – Federal budget cuts have put pressure...
08-15 00:22
Elicio Therapeutics Publishes Follow-Up Data From Phase 1 AMPLIFY-201 Study In Nature Medicine
At extended median follow-up of 19.7 months, median overall survival ("OS") increased from 16.33 to 28.94 monthsClinical efficacy correlated with the magnitude of T cell responses specific to mutant-KRAS ("mKRAS")
08-12 20:11
